Relmada Therapeutics (RLMD) Stock Overview
Operates as a clinical-stage biotechnology company in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
RLMD Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Relmada Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.60 |
| 52 Week High | US$5.12 |
| 52 Week Low | US$0.24 |
| Beta | 0.74 |
| 1 Month Change | 9.79% |
| 3 Month Change | 154.14% |
| 1 Year Change | 1,101.04% |
| 3 Year Change | 31.81% |
| 5 Year Change | -85.66% |
| Change since IPO | -92.33% |
Recent News & Updates
Recent updates
Relmada Therapeutics: Run Up Into Results May Resume Following This Drop
Mar 21Here's Why We're Watching Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation
Mar 13
Relmada: Phase 3 Data Did Not Live Up To Phase 2 Benchmark
Jan 14Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?
Dec 04Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?
Aug 29We're Keeping An Eye On Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate
May 07We're Keeping An Eye On Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate
Dec 15Relmada Downgraded at Truist, Guggenheim in wake of depression candidate failure
Oct 14Relmada Therapeutics: Initiating With A Strong BUY; Key Phase 3 Short-Term Catalysts Lined Up
Sep 14Relmada Therapeutics receives FDA fast track tag for REL-1017 to treat depression
Aug 09We're Hopeful That Relmada Therapeutics (NASDAQ:RLMD) Will Use Its Cash Wisely
Jul 14Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?
Feb 264 Clinical Catalysts On Tap For Relmada In 2022
Jan 28Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?
Nov 04Our First Look At Relmada Therapeutics
Jun 28We're Not Very Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate
Jun 28Here's Why We're Not Too Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation
Mar 09What Percentage Of Relmada Therapeutics, Inc. (NASDAQ:RLMD) Shares Do Insiders Own?
Jan 15
Shareholder Returns
| RLMD | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 5.7% | 2.7% | 3.1% |
| 1Y | 1,101.0% | 25.1% | 14.6% |
Return vs Industry: RLMD exceeded the US Pharmaceuticals industry which returned 25.1% over the past year.
Return vs Market: RLMD exceeded the US Market which returned 14.6% over the past year.
Price Volatility
| RLMD volatility | |
|---|---|
| RLMD Average Weekly Movement | 16.5% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RLMD's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: RLMD's weekly volatility has decreased from 22% to 17% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 17 | Sergio Traversa | www.relmada.com |
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. It also develops REL-P11, a modified-release formulation of psilocybin that has completed Phase 1 safety study for the treatment of metabolic disease.
Relmada Therapeutics, Inc. Fundamentals Summary
| RLMD fundamental statistics | |
|---|---|
| Market cap | US$337.33m |
| Earnings (TTM) | -US$56.17m |
| Revenue (TTM) | n/a |
Is RLMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RLMD income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$56.17m |
| Earnings | -US$56.17m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.77 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did RLMD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/26 01:08 |
| End of Day Share Price | 2025/12/24 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Relmada Therapeutics, Inc. is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Maxim Jacobs | Edison Investment Research |
| Farzin Haque | Jefferies LLC |
| Andrew Tsai | Jefferies LLC |